Balancing of Benefits and Harms
➤ The potential benefits of this guideline statement were viewed as far
outweighing the potential harms. The majority of individuals with
moderate to severe or disabling tardive dyskinesia would have a greater
likelihood of experiencing benefits of a VMAT2 inhibitor than experiencing
harms. Patient preferences to reduce motor signs and symptoms are also
likely to favor treatment.
Patient Preferences
➤ Clinical experience suggests that most patients with moderate to severe
or disabling tardive dyskinesia wish to have a diminution of their motor
signs and symptoms. Most patients would be willing to take medication
to achieve a reduction in motor signs and symptoms, particularly if it was
well tolerated.
